AYTU BIOPHARMA, INC Selling and Marketing Expense
AYTU BIOPHARMA, INC (AYTU) reported Selling and Marketing Expense of $23.37 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-09-22
- AYTU BIOPHARMA, INC selling and marketing expense for the quarter ending 2026-06-30 was $6.12M, a 28.01% increase year-over-year.
- AYTU BIOPHARMA, INC selling and marketing expense for the quarter ending 2026-03-31 was $5.93M, a 14.15% increase year-over-year.
- AYTU BIOPHARMA, INC selling and marketing expense for the quarter ending 2025-12-31 was $6.00M, a 13.77% increase year-over-year.
- AYTU BIOPHARMA, INC selling and marketing expense for the quarter ending 2025-09-30 was $5.32M, a 5.96% decline year-over-year.
- AYTU BIOPHARMA, INC selling and marketing expense for fiscal 2026 was $23.37M, a 11.78% increase from fiscal 2025.
- AYTU BIOPHARMA, INC selling and marketing expense for fiscal 2025 was $20.91M, a 5.33% decline from fiscal 2024.
- AYTU BIOPHARMA, INC selling and marketing expense for fiscal 2024 was $22.08M, a 46.72% decline from fiscal 2023.
- AYTU BIOPHARMA, INC selling and marketing expense for fiscal 2023 was $41.45M, a 7.06% increase from fiscal 2022.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $12.05M derived: sum of 2 quarters · filed 2026-09-22 | $18.05M derived: sum of 3 quarters · filed 2026-09-22 | $23.37M 10-K · filed 2026-09-22 | ||||
| 2026-03-31 | $5.93M 10-Q · filed 2026-05-13 | $11.93M derived: sum of 2 quarters · filed 2026-05-13 | $17.25M 10-Q · filed 2026-05-13 | $22.03M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-12-31 | $6.00M 10-Q · filed 2026-02-03 | $11.32M 10-Q · filed 2026-02-03 | $16.10M derived: sum of 3 quarters · filed 2026-09-22 | $21.30M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-09-30 | $5.32M 10-Q · filed 2025-11-13 | $10.10M derived: sum of 2 quarters · filed 2026-09-22 | $15.30M derived: sum of 3 quarters · filed 2026-09-22 | $20.57M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-06-30 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $9.97M derived: sum of 2 quarters · filed 2026-09-22 | $15.25M derived: sum of 3 quarters · filed 2026-09-22 | $20.91M 10-K · filed 2026-09-22 | ||||
| 2025-03-31 | $5.19M 10-Q · filed 2026-05-13 | $10.47M derived: sum of 2 quarters · filed 2026-05-13 | $16.13M 10-Q · filed 2026-05-13 | $21.55M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $5.27M 10-Q · filed 2026-02-03 | $10.93M 10-Q · filed 2026-02-03 | $16.35M derived: sum of 3 quarters · filed 2026-02-03 | $21.70M derived: sum of 4 quarters · filed 2026-02-03 | ||||
| 2024-09-30 | $5.66M 10-Q · filed 2025-11-13 | $11.08M derived: sum of 2 quarters · filed 2025-11-13 | $16.43M derived: sum of 3 quarters · filed 2025-11-13 | $21.65M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $10.77M derived: sum of 2 quarters · filed 2025-09-23 | $15.99M derived: sum of 3 quarters · filed 2025-09-23 | $22.08M 10-K · filed 2025-09-23 | $26.96M 10-K · filed 2024-09-26 | |||
| 2024-03-31 | $5.35M 10-Q · filed 2025-05-14 | $6.55M 10-Q · filed 2024-05-15 | $10.57M derived: sum of 2 quarters · filed 2025-05-14 | $16.66M 10-Q · filed 2025-05-14 | $20.55M 10-Q · filed 2024-05-15 | $24.64M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $5.22M 10-Q · filed 2025-02-12 | $6.58M 10-Q · filed 2024-02-14 | $11.31M 10-Q · filed 2025-02-12 | $14.00M 10-Q · filed 2024-02-14 | $19.29M derived: sum of 3 quarters · filed 2025-02-12 | $32.09M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-09-30 | $6.09M 10-Q · filed 2024-11-13 | $7.42M 10-Q · filed 2023-11-14 | $14.07M derived: sum of 2 quarters · filed 2024-11-13 | $26.88M derived: sum of 3 quarters · filed 2024-11-13 | $37.44M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $7.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $20.79M derived: sum of 2 quarters · filed 2024-09-26 | $31.35M derived: sum of 3 quarters · filed 2024-09-26 | $41.45M 10-K · filed 2024-09-26 | ||||
| 2023-03-31 | $12.80M 10-Q · filed 2024-05-15 | $23.36M derived: sum of 2 quarters · filed 2024-05-15 | $33.47M 10-Q · filed 2024-05-15 | $43.48M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $10.56M 10-Q · filed 2024-02-14 | $20.66M 10-Q · filed 2024-02-14 | $30.68M derived: sum of 3 quarters · filed 2024-02-14 | $40.42M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-09-30 | $10.10M 10-Q · filed 2023-11-14 | $20.11M derived: sum of 2 quarters · filed 2023-11-14 | $29.86M derived: sum of 3 quarters · filed 2023-11-14 | $39.52M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $19.76M derived: sum of 2 quarters · filed 2023-10-12 | $29.42M derived: sum of 3 quarters · filed 2023-10-12 | $38.71M 10-K · filed 2023-10-12 | ||||
| 2022-03-31 | $9.74M 10-Q · filed 2023-05-11 | $19.40M derived: sum of 2 quarters · filed 2023-05-11 | $28.70M 10-Q · filed 2023-05-11 | $40.88M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $9.66M 10-Q · filed 2023-02-21 | $18.96M 10-Q · filed 2023-02-21 | $31.14M derived: sum of 3 quarters · filed 2023-02-21 | $37.73M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-09-30 | $9.30M 10-Q/A · filed 2023-02-21 | $21.48M derived: sum of 2 quarters · filed 2023-02-21 | $28.07M derived: sum of 3 quarters · filed 2023-02-21 | $33.78M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $12.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $18.78M derived: sum of 2 quarters · filed 2022-09-27 | $24.48M derived: sum of 3 quarters · filed 2022-09-27 | $30.31M 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | $6.60M 10-Q · filed 2022-05-16 | $12.30M derived: sum of 2 quarters · filed 2022-05-16 | $18.13M 10-Q · filed 2022-05-16 | |||||
| 2020-12-31 | $5.71M 10-Q · filed 2022-02-14 | $11.53M 10-Q · filed 2022-02-14 | ||||||
| 2020-09-30 | $5.83M 10-Q · filed 2021-11-15 | |||||||
| 2020-06-30 | $11.40M 10-K · filed 2021-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |